Okogen announced completion of $3.3 million in financing to advance the company through its phase 2b clinical program for acute infectious conjunctivitis, as well as support development of an AI-driven image evaluation platform.
“This milestone reinforces our commitment to delivering comprehensive therapeutic solutions for patients suffering from [acute infectious conjunctivitis],” Joshua Moriarty, Okogen’s CEO, said in a company press release. “Our focus remains on developing innovative, first-in-class products that improve outcomes for patients and efficiency for